Who are Human papillomavirus quadrivalent vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): quadrivalent HPV vaccine, Gardasill 9™ vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/human-papillomavirus-quadrivalent-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Human papillomavirus quadrivalent vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human papillomavirus quadrivalent vaccine (Human papillomavirus quadrivalent vaccine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant virus-like particle vaccine. Area: Oncology / Immunology / Infectious Disease.

marketed Recombinant virus-like particle vaccine Human papillomavirus types 6, 11, 16, and 18 (L1 capsid protein) Oncology / Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Human papillomavirus quadrivalent vaccine (Human papillomavirus quadrivalent vaccine) — University of Alberta. This vaccine stimulates the immune system to produce antibodies against four types of human papillomavirus (HPV types 6, 11, 16, and 18) to prevent infection and associated diseases.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Human papillomavirus quadrivalent vaccine TARGET	Human papillomavirus quadrivalent vaccine	University of Alberta	marketed	Recombinant virus-like particle vaccine	Human papillomavirus types 6, 11, 16, and 18 (L1 capsid protein)
quadrivalent HPV vaccine	quadrivalent HPV vaccine	International Agency for Research on Cancer	marketed	Recombinant virus-like particle vaccine	HPV types 6, 11, 16, 18 (L1 major capsid protein)
Gardasill 9™ vaccine	Gardasill 9™ vaccine	Imperial College London	phase 3	Recombinant virus-like particle vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant virus-like particle vaccine class)

Imperial College London · 1 drug in this class
International Agency for Research on Cancer · 1 drug in this class
University of Alberta · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Human papillomavirus quadrivalent vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/human-papillomavirus-quadrivalent-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab